TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: number of days with headache per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDPR (Cumulative Disability Progression Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory muscle endurance capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bicycle time trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with vaccination schedules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined heart failure hospitalization and cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Change in weight (pounds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in BMI units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in MADRS total score at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (>or=50 reduction in MADRS total score) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (MADRS total score<or=12) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the number of papules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the grade of macular oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in passive permeability of fluorescein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in penetration ratio of fluorescein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of change in diameter in response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of respiratory distress
Endpoint domain: Adverse events/effects
Primary endpoint: proteinuria burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (CCI > or =6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CCI at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CCI at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the NEADL scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of pain registered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased pro-allergic cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decreased basophil activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psoriasis-related pain score improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriatic arthritis-related pain score improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wake time during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean marginal bone loss (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCS improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MCS improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dietary intake (lower glycemic load and less saturated fat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related social support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Rate of response to PRGF-Endoret
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute response to CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of vitamin B12 deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDI-2 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turnover index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage reduction of mean CFU count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to first statistically significant change from baseline on the Positive and Negative Syndrome Scale, Excited Component (PEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Global Impressions-Improvement (CGI-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number needed to treat (NNT) for requiring only one dose of study medication and no rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection rate of preinvasive lesions (dysplasia II‐III and CIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reproduction of a complex, sequential clinical skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in examination skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with learning skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in kidney function (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: increase in appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulmonary exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference in FEV(1) AUC(0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean difference in FVC AUC(0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of HAM-D score by 50%
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: coronary diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in electronic media use
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: first puncture success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rates of vascular puncture
Endpoint domain: Adverse events/effects
Primary endpoint: rates of subcutaneous bulging
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion to SR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No AF-related symptoms at 90 min
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Primary composite safety endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Area of harvest dysesthesia (percentage of the chest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of harvest dysesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: B&B mean score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: J-T task time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean mF-M score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from TLR
Endpoint domain: Mortality/survival
Primary endpoint: dp/dtmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulse pressure (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total in-hospital MACE during the first 7 days
Endpoint domain: Mortality/survival
Primary endpoint: Death occurred four years after PCI
Endpoint domain: Mortality/survival
Primary endpoint: MMP-9 serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum amyloid A (SAA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor necrosis factor-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BFCIrreg.SD measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BFCRadius measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue indices
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: postnatal growth acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of vertebral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean gastric volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: State Anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: World Health Organization Quality of Life Abbreviated version scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Unilateral spinal block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Central mixed oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic venous oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EEG complexity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean vertical pupillary diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients requiring oral steroids at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in irritability after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average twitch height (T1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SatO2 mean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory depression cases
Endpoint domain: Adverse events/effects
Primary endpoint: gastrointestinal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in free androgen index (FAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Depressive relapse
Endpoint domain: Adverse events/effects
Primary endpoint: flare (photon counts/ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological suppression at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prolonged duration of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rapid onset of action
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: vasoconstrictive action
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Composite ranking of relative risk according to KDIGO guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum level of Estradiol (E2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased likelihood of reaching a management decision
Endpoint domain: Life impact
Endpoint subdomain: Decision-making
Primary endpoint: Decreased decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: apoptosis rates of leukemia cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall satisfaction with treatment results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastroduodenal bicarbonate secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: s100A8/A9 ligand levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: anti-restenosis effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QMG Score for Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain with blood sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in clinic
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of acute delirium
Endpoint domain: Adverse events/effects
Primary endpoint: threshold stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: single-task sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dual-task sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Drug Liking
Endpoint domain: Adverse events/effects
Primary endpoint: Lower Drug High
Endpoint domain: Adverse events/effects
Primary endpoint: Lower Abuse Potential
Endpoint domain: Adverse events/effects
Primary endpoint: Mean antibiotic prescribing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in fasting proCPU concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drop-outs attributable to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: serum concentration of clomipramine and desmethylclomipramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of transient ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total duration of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma glucose concentrations during fasting periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of hypoglycaemic plasma glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerance of basal rate testing with negligible carbohydrate snacks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful ECV rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of infections
Endpoint domain: Adverse events/effects
Primary endpoint: NPQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of IC acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who initiated dialysis with PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritonitis rates per patient-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: maximum T-wave shape index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum relative T-wave residuum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of patient-related ventriculitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of EVD-related ventriculitis
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate in NSCLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opportunities for physical activity (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of physical activity (PA) students engage in
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival (OS) at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Progression-Free Survival (PFS) at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Seroprotective levels of measles virus antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-rubella virus immunoglobulin G (IgG) seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antirotavirus immunoglobulin A and IgG seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ASDAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gel distribution rate at the septum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gel distribution rate at the inferior turbinate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of four cycles of therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Estimated cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Vo2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in low density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Life in Late Stage Dementia
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequent use of portal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Beliefs about smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitudes towards smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction of supplemental albuterol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean length of CSF rhinorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MRS‐II score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive deficits in neuropsychological assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ovulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Luteinizing hormone/FSH ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in OCD severity on CGI-S OCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment responder criteria on CGI-I OCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: point prevalence abstinence rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: continuous abstinence rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: major adverse cardiac event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean value of SeDBP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reaching target blood pressure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total successful response rate to the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time from rupture to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive power of aEEG for anesthesia depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Testosterone (T) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: disinfection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of travelers' diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Incidences of ischemic cerebrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Plasma levels of inflammatory factors (Fib, PAgT, CRP, TMAO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Syndrome of fire-heat scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal cough responses to capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of surgical procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Circulating proinflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain oxygenation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance during hypoxia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adjacent caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes